-- 獨立研究機構CFRA向提供了以下研究報告。 CFRA分析師的觀點摘要如下：LH公佈第一季調整後每股盈餘為4.25美元，較去年同期成長10.6%，超出市場預期0.13美元，連續第11季業績超出預期。營收年增5.8%至35.4億美元，調整後營業利益率提升30個基點至14.4%，兩大業務板塊皆可成長。診斷實驗室業務表現穩定，營收成長5.0%至27.6億美元；生物製藥實驗室服務業務成長8.2%至7.806億美元，主要得益於中心實驗室的強勁表現。管理層上調了全年業績預期，將調整後每股收益中位數上調0.13美元至18.03美元，並將營收成長預期上調20個基點，體現了對公司業務發展前景的信心。現金流狀況顯著改善，自由現金流為7050萬美元，去年同期為負1.075億美元。 LH維持了均衡的資本配置，在併購方面投資2.022億美元，同時透過股票回購和分紅向股東返還1.592億美元。我們認為，86.4億美元的積壓訂單以及1.04的過去12個月訂單出貨比支撐了收入的可見度。
Related Articles
Research
Research Alert: CFRA Keeps Buy Opinion On Shares Of Firstenergy Corp.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We trim our 12-month target by $1 to $55, 20.0x our next-12-month EPS view of $2.75, a premium to its five-year average of 15.6x. We reduce our 2026 EPS view by $0.02 to $2.72 and 2027 EPS by $0.01 to $2.93. The Q1 core EPS increase (+7.5% Y/Y) breaks a three-quarter streak of declines, and we see continued momentum throughout our forecast horizon. We see positive data center demand trends, with long-term contracted demand (4.3 GW) up 4% since February 2026 (4.1 GW) and up 47% since February 2025 (2.9 GW), while pipeline demand (14.9 GW) is up 15% since February 2026 (12.9 GW) and has more than doubled since February 2025 (6.1 GW). FE has reduced base O&M by over $200M (15%) since 2022, with Q1 2026 showing an additional ~5% YoY decline, while simultaneously improving reliability metrics. We think FE's cost discipline, service quality improvement, and competitive rate positioning should translate into more favorable rate case outcomes, reduced disallowance risk, and potentially higher allowed ROEs.
$FE
Sectors
Sector Update: Consumer
Consumer stocks were higher Thursday afternoon, with the State Street Consumer Staples Select Sector SPDR ETF (XLP) rising 1.4% and the State Street Consumer Discretionary Select Sector SPDR ETF (XLY) increasing 0.4%.In corporate news, Lamb Weston (LW) shares rose 1.6% after shareholder Starboard Value said in a letter to the board Thursday that the company should hold an investor day and reset earnings to a normalized level.
$LW
Australia
Market Chatter: FDA Panel Votes Against Benefits of AstraZeneca's Breast Cancer Drug
The US Food and Drug Administration's Oncology Drugs Advisory Committee rejected the benefits AstraZeneca's (AZN) Camizestrant drug candidate to treat breast cancer, Bloomberg reported Thursday.Six committee members voted against the drug due to disagreement over the trial design and the potential implications in the clinical setting, according to Bloomberg.The drug trial met is primary endpoint of progression-free survival as well as the progression-free survival 2 endpoint, however, FDA does not consider PFS2 a suitable endpoint for regulatory decision making, according to a briefing document.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $189.60, Change: $+4.40, Percent Change: +2.37%
$AZN